SIAIS562055 and BCR–ABL inhibitors synergistically enhanced inhibition of ABL phosphorylation and downstream signaling, demonstrating robust antitumor activities in both mouse xenografts and primary samples from patients with CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.